AbbVie (ABBV) Amortizatization of Intangibles (2012 - 2026)

AbbVie (ABBV) posted quarterly Amortizatization of Intangibles of $1.7 billion for Q1 2026, down 8.5% YoY from $1.9 billion in Q1 2025, and down 4.33% sequentially from $1.8 billion in Q4 2025.

AbbVie (ABBV) Amortizatization of Intangibles (2012 - 2026) Analysis & Trends

AbbVie has disclosed Amortizatization of Intangibles across 15 years of filings, most recently posting $1.7 billion for Q1 2026.

  • In Q1 2026, Amortizatization of Intangibles fell 8.5% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $7.3 billion (down 3.39% YoY), while the FY2025 annual figure was $7.4 billion, down 2.93% from the prior year.
  • Amortizatization of Intangibles eased to $1.7 billion in Q1 2026, from $1.8 billion in the prior quarter.
  • Over the last five years, Amortizatization of Intangibles for ABBV reached as high as $2.1 billion in Q2 2023 and fell as low as $1.7 billion in Q1 2026.
  • The 5-year median for Amortizatization of Intangibles is $1.9 billion (2024), against an average of $1.9 billion.
  • Annual changes were most pronounced in 2022 — Amortizatization of Intangibles slipped 10.0% — and 2023, when it rose 16.67%.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $2.0 billion in 2022, then decreased by 7.85% to $1.8 billion in 2023, then increased by 1.68% to $1.9 billion in 2024, then dropped by 5.18% to $1.8 billion in 2025, then dropped by 4.33% to $1.7 billion in 2026.
  • According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $1.7 billion, $1.8 billion, and $1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amort. of Intangibles (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 1.70 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 931.00 Mn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 596.00 Mn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn 107.60 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.70 Bn
Mar 31, 2026 1.70 Bn
Dec 31, 2025 1.78 Bn
Dec 31, 2025 1.78 Bn
Sep 30, 2025 1.90 Bn
Sep 30, 2025 1.90 Bn
Jun 30, 2025 1.90 Bn
Jun 30, 2025 1.90 Bn
Mar 31, 2025 1.86 Bn
Mar 31, 2025 1.86 Bn
Dec 31, 2024 1.87 Bn
Dec 31, 2024 1.87 Bn
Sep 30, 2024 1.90 Bn
Sep 30, 2024 1.90 Bn
Jun 30, 2024 1.90 Bn
Jun 30, 2024 1.90 Bn
Mar 31, 2024 1.90 Bn
Mar 31, 2024 1.90 Bn
Dec 31, 2023 1.84 Bn
Dec 31, 2023 1.84 Bn